The Malassezia yeast is the causative agent in dandruff and seborrhoeic dermatitis. NovaBiotics has applied the same biotechnology and drug discovery expertise with which it has already generated clinical stage antifungal candidate medicines to develop technology that kills Malassezia organisms. NovaBiotics’ patent pending Luminaderm® peptides kill both the sebum (lipid) and non-sebum-dependent variants of the yeast and provide GRAS, non-irritant alternatives to the active ingredients in currently available anti-dandruff and seborrhoeic dermatitis products (e.g. selenium, zinc, sulphur, tar and antifungal shampoos);not all of which target all Malassezia forms.

 

Frequent exposure of the scalp and hair to currently available anti-dandruff products can lead to poor hair condition and dry scalp, due to the active ingredients themselves and/or the formulations it is necessary to use. As a result, compliance with and long-term success of many anti-dandruff and dermatitis treatments is, on the whole, poor. In addition to their proven antifungal effects against all Malassezia yeasts tested, Luminaderm® peptides contain amino acids that are known to improve hair condition and that can be delivered in cosmetically acceptable, hair and scalp hydrating formulae. These safe, hair and scalp-friendly antifungal agents are already approved for use in a number of consumer health products, supplements and medicines. As with all NovaBiotics antimicrobial compounds Luminaderm® peptides minimise, if not negate, the risk of antimicrobial drug resistance developing in the target yeast. This is not the case for the conventional antifungal ingredients used in many conventional anti-dandruff and dermatitis treatments.

Please click here for details of our available Data Package